Get all your news in one place
100’s of premium titles. One news app. Zero ads. Just $10 per month.

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ:NTLA) presented additional data from the Phase 1 trial for NTLA-2001 in transthyretin, or ATTR, amyloidosis.

  • In the initial study, Intellia showed that a single infusion of its gene-editing therapy could lower the amount of toxic protein in six patients by an average of 52% or 87%, depending on the dose
  • The new results showed that a slightly higher dose produced similar results. An even higher one could reduce protein expression by an average of 93% across six patients, with minimal side effects. 
  • The most common adverse events across 15 patients in the study were mild symptoms such as rash and nausea. 
  • One dose-limiting toxicity was observed in a patient who experienced vomiting, rated as a grade 3 adverse event.
  • Intellia confirmed that the reduction in serum levels of the transthyretin (TTR) was maintained in patients after follow-up ranging from two months to 12 months post-treatment.
  • Intellia leads the development and commercialization of NTLA-2001 as part of a collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
  • Price Action: NTLA shares traded 8.32% lower at $90.63 during pre-market trading on Tuesday.
Related Stories
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Intellia successfully lowered a problematic protein in patients with a liver disease on Monday, but NTLA stock fell on a…
One subscription that gives you access to news from hundreds of sites
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours:
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday.
80 Biggest Movers From Yesterday
Gainers  
See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial
The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ:FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile…
One subscription that gives you access to news from hundreds of sites
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours.